**Name of Journal: *World Journal of Gastrointestinal Oncology***

**ESPS Manuscript NO: 26301**

**Manuscript Type: Original Article**

***Retrospective Study***

**Signet ring colorectal carcinoma: Do we need to improve the treatment algorithm?**

TamhankarAS *et al.* Signet ring cell colorectal carcinoma

**Anup Sunil Tamhankar, Parag Ingle, Reena Engineer, Munita Bal,Vikas Ostwal, Avanish Saklani**

**Anup Sunil Tamhankar, Dr Parag Ingle,** Department of Surgical Oncology, Tata Memorial Centre, Mumbai, Maharashtra 400012, India

**Reena Engineer,** Department of Radiotherapy, Tata Memorial Centre, Mumbai, Maharashtra 400012, India

**Munita Bal**, Department of Surgical Pathology, Tata Memorial Centre, Mumbai, Maharashtra 400012, India

**Vikas Ostwal,** Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra 400012, India

**Avanish Saklani,** Department of Gastro-Intestinal Surgery, Tata Memorial Centre, Mumbai, Maharashtra 400012, India

**Author contributions:** All authors contributed to the manuscript.

**Institutional review board statement:** We hereby declare that the institutional review board has inspected and approved this retrospective study.

**Informed consent statement:** We hereby declare that waiver of consent has been obtained for this retrospective study from Institutional Review Board due to lack of direct patient contact. Also this study doesn’t disclose the identity or private information of any of the study patients.

**Conflict-of-interest statement:** No potential conflicts of interest relevant to this article were reported.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Dr. Avanish Saklani, MS, FRCS, Associate Professor,** Department of Gastro-Intestinal Surgery**,** Tata Memorial Centre, Mumbai, Maharashtra 400012, India. asaklani@hotmail.com

**Telephone**: +91-996-9506719

**Fax**: +91-222-4177000

**Received:** April 2, 2016

**Peer-review started:** April 7, 2016

**First decision:** June 6, 2016

**Revised:** July 11, 2016

**Accepted:** September 13, 2016

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To elaborate about this peculiar variant from a tertiary cancer center from India.

***METHODS***

It’s a retrospective study (2011-2014) of all patients diagnosed with signet ring colo-rectal cancer (SRCC). Various clinico-pathological variables were studied.

***RESULTS***

One hundred and seventy consecutive patients with SRCC were diagnosed (11.4% of all colorectal cancers). Median Age of the cohort was 41 years. Most common location was recto-sigmoid area (54.7%). Majority patients presented in stage III and IV (91.2%). Most of the stage IV patients had isolated peritoneal metastases (86.5%). Colonic tumors had higher incidence of peritoneal metastases (91.8% *vs* 83.3%) as well as isolated peritoneal recurrences (37.5% *vs* 16.7%) than rectal primaries.Thirty-seven point five percent of patients recurred after curative surgery. Amongst them 63.63% patients had isolated peritoneal recurrences. Circumferential resection margin (CRM) was involved in 17.9% patients.Median relapse free survival (RFS) and overall survival (OS) of the cohort were 14.9 and 18.13 mo respectively. CRM involvement, colonic primary were associated with poorer RFS and OS.

***CONCLUSION***

SRCC has predilection for peritoneal dissemination. More aggressive and/or extended chemotherapy schedules as well as prophylactic hyperthermic intra-peritoneal chemotherapy at the time of primary surgery may be attempted in these patients.

**Key words:** Colorectal Cancer; Signet ring cell carcinoma; Peritoneal metastases; Hyperthermic intra-peritoneal chemotherapy

**©The Author(s) 2016.**Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The incidence of Signet Ring Colo-Rectal Cancer appears to be higher in Indian subcontinent than the world literature. It has predilection for peritoneal lining. It affects younger age group. Majority cases present in stage III and IV. Recto-sigmoid region is affected commonly. The most common metastatic site and site of recurrence is peritoneal cavity. Probably it should be treated with a different protocol than the conventional adenocarcinoma with focus on aggressive peritoneal cytoreductions and hyperthermic intra-operative intraperitoneal chemotherapy (HIPEC). Further research is needed to evaluate molecular biology of this variant and utility of prophylactic HIPEC during curative surgery.

Tamhankar AS, Ingle P, Engineer R, Bal M, Ostwal V, Saklani A. Signet ring colorectal carcinoma: Do we need to improve the treatment algorithm? *World J Gastrointest Oncol* 2016; In press

**INTRODUCTION**

Colorectal cancer (CRC) is one of the most common cancers worldwide[1]. There are three subtypes described in the literature based on the amount and location of mucin in the tumor. These are conventional adenocarcinoma (AC), mucinous carcinoma (MC) and signet ring cell carcinoma (SRCC)[2,3]. SRCC constitutes 1% of all colorectal carcinomas[4-9]. It is an aggressive variant which affects younger population & has poorer prognosis[5]. The literature explaining the biology as well as the optimum treatment algorithm of this particular variant is scarce due to its low incidence. So we look into the incidence, demographics, clinico-radiological presentation and outcome of treatment of this peculiar variant from a tertiary cancer centre from India (Tata Memorial Centre, Mumbai).

**MATERIALS AND METHODS**

All patients diagnosed with colorectal carcinoma from 1st January 2011 to 31st December 2013, registered under the Department of Gastro-intestinal Oncology services, Tata Memorial Centre, were included. The data was collected retrospectively from Electronic database as well as case files from Department of Surgical Oncology. The histopathology specimens of all these patients were reviewed at Department of Surgical pathology, Tata Memorial Centre. Signet ring cell colorectal cancers were defined as per WHO criteria (adenocarcinoma with more than 50% of signet-ring cells). Patients were staged as per AJCC classification (7th edition). Response to Neoadjuvant chemo-radiotherapy (NACTRT) was assessed as per RECIST criteria. The decision about the same was taken in the multidisciplinary meeting held for every patient. Pathological complete response was defined as absence of viable tumor cells in the primary, the lymph nodes and peri-rectal soft tissue. Circumferential Resection Margin (CRM) positivity was defined as presence of viable tumor cells at or within 1 mm of it. Follow up data was obtained from electronic medical records and/or telephonic questionnaire. Recurrences were based on biopsy or strong clinico-radiological evidence. Peritoneal metastases or recurrences constituted peritoneal deposits, malignant ascites, omental deposits and ovarian deposits. Relapse free survival (RFS) was assessed from the date of cancer directed surgery to date of recurrence. Overall survival (OS) was measured from the date of diagnosis of malignancy to date of death. SPSS-21 (IBM corporation) was used for the statistical analysis. Categorical variables were compared with Chi-square test. Survival functions were analyzed with Kaplan Meir curves and compared with log rank test.

**RESULTS**

From 1st January 2011-31st December 2013, 1487 patients with colorectal cancer got registered under the department of Gastrointestinal Services Tata Memorial Centre. Amongst them, signet ring cell carcinoma was diagnosed in 170 consecutive patients (11.4%). Follow up of 18 of 170 patients (10.58%) was inadequate (< 1 mo) (Table 1). Median Age of the cohort was 41 years. Males were affected nearly twice more than females (M: F = 1.8: 1). Most tumors were located in the rectum and sigmoid colon (Rectum: 41.2% and Sigmoid: 13.5%). Majority patients presented in stage III (51.8%) and stage IV (39.4%). Most of the stage IV patients had isolated peritoneal metastases (58/67, 86.5%) (Table 2). Curative surgery was feasible only in 51.76% (88/170) patients. 37.5% (33/88) patients recurred after curative surgery. 21/33(63.63%) patients had isolated peritoneal recurrences (Table 3). Most patients had high nodal burden, pN1 being 23.2% (22/95), pN2 being 57.9% (55/95). Amongst node positive patients, 66.3% (53/77) had perinodal extension. The rate of lymph node metastases and lympho-vascular invasion increased progressively with increasing pathological T stage.

Median relapse free survival (RFS) and overall survival (OS) of the cohort were 14.9 months and 18.13 mo respectively. OS of peritoneal and non-peritoneal metastases were equivalent (16 mo *v/s* 13 mo, *P* = 0.729) (Table 4).

 Forty-eight rectal cancers were operated. Data for patients undergoing neo-adjuvant chemoradiation (NACTRT) was available for 37 cases only. Pathological complete response was seen in 21.6% (8/37) patients. Circumferential resection margin (CRM) was involved in 17.9% (7/39) patients (Data on CRM was not available for 9 cases). CRM involvement was associated with poorer RFS (15 mo *vs* 37.2 mo, *P* = 0.060) and OS (19.9 mo *vs* 41.5 mo, *P* = 0.018) as compared to patients with uninvolved CRM (Tables 4 and 5).

The location of primary had a significant impact on the clinico-pathological outcome of the patient. As compared to rectal primaries, colonic tumors had higher incidence of peritoneal metastases (83.3% *vs* 91.8%, *P* = 0.074) as well as isolated peritoneal recurrences (16.7% *vs* 37.5%, *P* = 0.062). Colonic primaries were associated with poorer OS than rectal tumors after curative resection (32.298 mo *vs* 40.089 mo, *P* = 0.058) and RFS (24.74 mo *vs* 34.02 mo, *P* = 0.048) (Table 6).

**DISCUSSION**

Colorectal cancer (CRC) is one of the most common cancers worldwide. Worldwide, it leads to 10% and 9.2% of cancers in males and females respectively. It is a cause of 8% and 9% of cancer related deaths in males and females respectively[1]. Several histological subtypes have been reported[2,3]. It has two different subgroups apart from classical adenocarcinoma (AC). They are classified based on varying amounts of signet-ring cell and/or mucinous component. Signet-ring cell carcinoma (SRCC) is characterized by intra-cytoplasmic mucin which displaces the nucleus aside. Mucinous carcinoma (MC) is characterized by extracellular mucin pools. SRCC or MC (defined as carcinoma with more than 50% of signet-ring cells or mucinous component, respectively as per WHO classification) constitutes approximately 1% or 5%–15 % of CRC cases, respectively in the world literature[4-9]. As compared to the world literature, the incidence of SRCC is much higher in our study (11.4% *vs* 1%). The median age of the cohort in our study was also lower than world literature (41years *vs* 50-55 years)[5,6,10,11]. This could represent either a referral bias being a tertiary cancer centre in India or definite distinct disease biology in the Indian population. Further studies regarding the demographic profile of this particular variant in Indian population are under consideration currently.

The literature is divided about the most common site of colorectal cancer in young population with some indicating proximal colon[12] and others suggesting it to be recto-sigmoid region[13,14]. In our study, rectum and sigmoid colon region was most commonly affected. This may be related to preferential referral of locally advanced rectal cases to our institute. One of the studies has shown that colorectal cancers affecting younger age group (< 40 years) have significantly higher incidence of signet ring cell cancer. Such tumors also affect rectosigmoid area more commonly than rest of the colon in young patients[15].

Signet-ring cell carcinoma has been associated with peculiar genomic changes such as high-degree microsatellite instability (MSI-high) (up to 40%), high-frequency of CpG island methylator phenotype (CIMP-high), higher methylation level of long interspersed nucleotide element-1 (LINE-1) and frequent BRAF mutation and low COX-2 expression[8,16-20]. Due to high frequency of MSI-H mutations[21] and associated poor prognosis, tumors with signet ring histo-morphology are recommended to be screened for MSI-H mutations as per revised Bethesda guidelines[22].The serrated adenoma-carcinoma pathway has been proposed for development of these tumors. Terada *et al*[23] found that epithelial membrane antigen (EMA) was downregulated in colorectal SRCC. Kim *et al*[24] showed that focal loss of EpCAM (Epithelial cell adhesion molecule) was associated with development of SRCC in colonocytes. These molecular changes may be related to preferential peritoneal spread of this subtype. Currently the studies are under consideration at our institute to assess genomic changes related to this specific phenotype which may be the cause of higher incidence of signet ring colorectal cancer in Indian population than the world literature.

Our study revealed that, though SRCC has an aggressive biology in general, it seems to respond well to neoadjuvant chemo-radiation (NACTRT) with pathological complete response rate of 21%. Literature assessing response of SRCC to NACTRT is scarce due to low incidence worldwide. Jayanand *et al*[25] showed that these tumors respond well to RT with high pathological complete response (pCR) rates. It may be related to their aggressive nature and higher mitotic index. So potentially NACTRT should be included in the treatment protocol of rectal SRCC for improved outcomes.

 Patients with SRCC are more likely to present in advanced stages (Stage III/IV) than AC. SRCC patients more often present with metastatic disease and are more likely to develop peritoneal metastases. This may be related to their peculiar molecular origin which is yet to be proven. It is also shown that SRCC metastasizes to the lymph nodes, whereas AC metastasizes primarily to the liver[6,9,11]. Our study also showed similar findings.

SRCC has been associated with a poor prognosis compared with AC[5,6,10,11]. Studies have shown that peritoneal metastases of SRCC are associated with a poorer prognosis, and survival is even worse if other organs are also affected[26]. But in our study, patients with peritoneal metastases had similar OS as compared to those with non-peritoneal metastases. This may be due to small sample size of the study. Often, these metastases cannot be treated with curative intent. As of now, curative surgery is an option mainly limited to liver and lung metastases, which are the most common metastatic sites in AC patients. Systemic chemotherapy for peritoneal metastases may not yield the same results compared with hematogenous metastases due to blood-peritoneal barrier. As a result, outcome is poor in advanced SRCC cases[27].

The incidence of synchronous and metachronous peritoneal metastases in colorectal carcinoma (AC) seems to be in the range of 4%-5% (much lower than with SRCC)[26,28]. Studies have revealed that peritoneal carcinomatosis among patients with metastatic colorectal cancer is associated with a 30% reduction in overall survival (10.7mo *vs* 17.6 mo)[29]. The overall survival of these patients is found to be less than 6 mo despite the use of 5FU andleucovorin based chemotherapy[30,31]. But palliative surgery and systemic chemotherapy, together have been shown to improve survival upto 12 mo in patients with isolated peritoneal metastases[29,32].

Hyperthermic intra-operative intra-peritoneal chemotherapy (HIPEC) has shown promising results for peritoneal metastases of colorectal origin[29]. Verwaal *et al*[29] reported outcome of 1427 patients with peritoneal metastases of colorectal origin treated with cytoreductive surgery (CRS) and HIPEC. Peri-operative morbidity and mortality were 34% and 3% respectively. Median hospital stay was 16 days. Median PFS was 15 mo and OS was 33 mo. Three- and five-year survival rates were 46% and 31 % respectively. So authors concluded that CRS and HIPEC seems to be safe & beneficial in peritoneal metastases of colorectal origin[33]. But literature assessing benefit of HIPEC for SRCC is scarce and controversial with studies denying[34,35] and implying[36] benefit of HIPEC in this subgroup. But these reports are retrospective and are fraught with small sample sizes.

Recently, Hao *et al*[37] have proposed a study assessing the benefit of monoclonal antibody blocking EpCAM in CRC. This may be relevant in the further management of SRCC as EpCAM also has altered expression in this subtype.

Klaver *et al*[38] have proposed a randomized controlled trial (COLOPEC) for assessing benefit of prophylactic HIPEC in patients at high risk of peritoneal carcinomatosis. They have included patients (non-metastatic) with T4 disease or on table tumor site perforation for prophylactic HIPEC followed by routine adjuvant chemotherapy. It has been postulated in assumption that very few patients with peritoneal carcinomatosis become eligible for CRS and HIPEC; as a result they have poor prognosis. So if a prophylactic HIPEC reduces the occurrence of peritoneal metastases in future, it may result in benefit in OS. The investigators have not considered signet ring cell pathology as inclusion criteria for the study; probably because of low incidence (1%-2%) of it in the western literature. A similar study may be considered in Indian patients with signet ring cell carcinoma to assess benefit of prophylactic HIPEC at the time of primary surgery as it has a peculiar tendency for isolated peritoneal recurrences and the incidence of this particular histopathological subtype seems to be higher in them (11.4%) as suggested by present study.

It is unclear whether different histological subtypes should influence treatment decisions, since it is often not addressed in clinical trials. In the literature, studies concerning outcome after adjuvant or palliative chemotherapy for SRCC are rare. However, due to the aggressive behavior and high incidence of SRCC in young patients, it is imperative to develop understanding of potential adjuvant treatment options as it is likely to alter quality of life and have significant socio-economic impact. Colonic SRCC are more likely to have peritoneal dissemination and poorer survival than rectal SRCC. So more aggressive treatment options, like HIPEC may be useful in these patients at the time of primary surgery or after peritoneal limited recurrence in order to improve survival and quality of life. This can only be addressed in a randomized control trial setting. Due to high nodal disease burden and high incidence of failure after curative surgery (up to 40%), more extended and/or aggressive adjuvant chemotherapy options should also be explored in this subset of population which is younger and is likely to tolerate the aggressive treatment better.

Signet ring colorectal cancer has poor prognosis. It has a higher incidence in Indian subcontinent. It affects young patients and has predilection for peritoneal dissemination.

Isolated peritoneal metastases as well as isolated peritoneal recurrences are very frequent in these patients. SRCC responds well to radiation. So whenever indicated, neoadjuvant radiation should be included in the treatment protocol for rectal SRCC.

More aggressive and/or extended chemotherapy schedules as well as prophylactic HIPEC at the time of primary surgery, especially for colonic tumors, should be explored in a trial setting in order to improve dismal survival in these patients.

**COMMENTS**

***Background***

Signet Ring Colorectal cancer (SRCC) is a subtype of colorectal adenocarcinoma. It tends to affect younger age group. Most of the patients present in stage III or IV. The most common site affected is rectosigmoid region. It has a peculiar affection for peritoneal lining. Most of the metastases and recurrences happen exclusively in the peritoneal cavity. Visceral metastases are rare. Average prognosis of these patients is poor. There is no effective adjuvant or palliative treatment for this entity. Early studies in the field of cytoreductionandhyperthermic intra-operative intraperitoneal chemotherapy (HIPEC) have shown promising results and prolongation of survival in peritoneal carcinomatosis of colorectal cancer. The trials are underway to test the impact of prophylactic HIPEC during primary surgery for cT4N1/2 diseases. Since SRCC has a different natural course than the conventional adenocarcinoma of colon, it may be worthwhile to evaluate the possible role of extended chemotherapy or prophylactic HIPEC at the time of curative surgery for SRCC.

***Research frontiers***

Currently trials are underway (COLOPEC andProphylochip) to assess efficacy of prophylactic HIPEC in high risk colorectal cancers to prevent occurrence of peritoneal metastases and prolongation of survival. Though aggressive, SRCC has shown its peculiar nature to remain confined to peritoneal cavity in majority patients. This makes it a potential target for peritoneum directed therapies (Cytoreductionand HIPEC). Also monoclonal antibodies blocking EpCAM are being evaluated in CRC. This may be relevant in the further management of SRCC as EpCAM also has altered expression in this subtype.

***Innovations and breakthroughs***

Cytoreductionand HIPEC has shown survival benefit in peritoneal carcinomatosis of colorectal origin in a large randomized trial by Verwaal*et al* SRCC has not been evaluated widely in the western literature, probably due to lower incidence. But in Indian subcontinent, the incidence of this disease entity appears to be higher than rest of the world. It also affects younger population; as a result has significant bearing on the socioeconomic outcome of entire family. There is a strong need to develop a modified treatment protocol for this disease than conventional adenocarcinoma as the disease biology appears to be different and standard chemotherapy doesn’t act well on the peritoneal disease. Certain molecular abnormalities are also noted in SRCC such as high microsatellite instability (MSI-H), EpCAM mutations, high-frequency of CpG island methylator phenotype (CIMP-high), higher methylation level of long interspersed nucleotide element-1 (LINE-1) and frequent BRAF mutation and low COX-2 expression. Further research needs to be carried out to understand the biology of this disease entity well which might give us an insight into potential treatment options for the same.

***Applications***

To summarize, SRCC seems to be a suitable target for peritoneum directed therapies which include aggressive cytoreduction& HIPEC. Extended/ modified chemotherapy protocols may improve survival. Further understanding of molecular biology of this disease may open new methods for its treatment.

***Peer-review***

It is a retrospective study of an uncommon subtype of colorectal carcinoma. The author statisized some information of this cancer including the age, location, stages, metastasis, recurrence and survival.

**REFERENCES**

1 **Ferlay J,** Soerjomataram I, Ervik M. World Stats GLOBOCAN v1.0, IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer, 2013. Available from: URL: http: //globocan.iarc.fr/Pages/fact\_sheets\_population.aspx

2 **Jemal A**, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; **61**: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]

3 **Weitz J**, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. *Lancet* 2011; **365**: 153-165 [PMID: 15639298 DOI: 10.1016/S0140-6736(05)17706-X]

4 **Bosman FT**, Carneiro F, Hruban RH, Theise ND. (2010) WHO classification of tumours of the digestive system. 4th edition. Geneva: International Agency for Research on Cancer.

5 **Chew MH,** Yeo SA, Ng ZP, Lim KH, Koh PK, Ng KH, Eu KW. Critical analysis of mucin and signet ring cell as prognostic factors in an Asian population of 2,764 sporadic colorectal cancers. *Int J Colorectal Dis* 2010; **25**: 1221–9 [PMID: 20686777 DOI: 10.1007/s00384-010-1033-3]

6 **Hyngstrom JR**, Hu CY, Xing Y, You YN, Feig BW, Skibber JM, Rodriguez-Bigas MA, Cormier JN, Chang GJ. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. *Ann SurgOncol* 2012; **19**: 2814-2821 [PMID: 22476818 DOI: 10.1245/s10434-012-2321-7]

7 **Nitsche U**, Zimmermann A, Späth C, Müller T, Maak M, Schuster T, Slotta-Huspenina J, Käser SA, Michalski CW, Janssen KP, Friess H, Rosenberg R, Bader FG. Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. *Ann Surg* 2013; **258**: 775-82; discussion 782-3 [PMID: 23989057 DOI: 10.1097/SLA.0b013e3182a69f7e]

8 **Gopalan V**, Smith RA, Ho YH, Lam AK. Signet-ring cell carcinoma of colorectum--current perspectives and molecular biology. *Int J Colorectal Dis* 2011; **26**: 127-133 [PMID: 20686774 DOI: 10.1007/s00384-010-1037-z]

9 **Hugen N**, van de Velde CJ, de Wilt JH, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. *Ann Oncol* 2014; **25**: 651-657 [PMID: 24504447 DOI: 10.1093/annonc/mdt591]

10 **Song W**, Wu SJ, He YL, Cai SR, Zhang CH, Zhang XH, Zhan WH. Clinicopathologic features and survival of patients with colorectal mucinous, signet-ring cell or non-mucinous adenocarcinoma: experience at an institution in southern China. *Chin Med J* (Engl) 2009; **122**: 1486-1491 [PMID: 19719934]

11 **Chen JS**, Hsieh PS, Hung SY, Tang R, Tsai WS, Changchien CR, Lin PY, Wang JY, Yeh CY. Clinical significance of signet ring cell rectal carcinoma. *Int J Colorectal Dis* 2004; **19**: 102-107 [PMID: 14752674 DOI: 10.1007/s00384-003-0515-y]

12 **Savas N**, Dagli U, Akbulut S, Yuksel O, Sahin B. Colorectal cancer localization in young patients: should we expand the screening program? *Dig Dis Sci* 2007; **52**: 798-802 [PMID: 17245629 DOI: 10.1007/s10620-006-9432-6]

13 **Meyer JE**, Narang T, Schnoll-Sussman FH, Pochapin MB, Christos PJ, Sherr DL. Increasing incidence of rectal cancer in patients aged younger than 40 years: an analysis of the surveillance, epidemiology, and end results database. *Cancer* 2010; **116**: 4354-4359 [PMID: 20734460 DOI: 10.1002/cncr.25432]

14 **Yantiss RK**, Goodarzi M, Zhou XK, Rennert H, Pirog EC, Banner BF, Chen YT. Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. *Am J SurgPathol* 2009; **33**: 572-582 [PMID: 19047896 DOI: 10.1097/pas.0b013e31818afd6b]

15 **Chang DT**, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM, Welton M, Shelton A, Ma L, Arber DA, Pai RK. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. *Mod Pathol* 2012; **25**: 1128-1139 [PMID: 22481281 DOI: 10.1038/modpathol.2012.61]

16 **Ogino S**, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G, Meyerhardt JA, Loda M, Fuchs CS. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. *Mod Pathol* 2006; **19**: 59-68 [PMID: 16118624 DOI: 10.1038/modpathol.3800482]

17 **Tanaka H**, Deng G, Matsuzaki K, Kakar S, Kim GE, Miura S, Sleisenger MH, Kim YS. BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. *Int J Cancer* 2006; **118**: 2765-2771 [PMID: 16381005 DOI: 10.1002/ijc.21701]

18 **Kakar S**, Deng G, Smyrk TC, Cun L, Sahai V, Kim YS. Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma. *Mod Pathol* 2012; **25**: 1040-1047 [PMID: 22522845 DOI: 10.1038/modpathol.2012.44]

19 **Kelemen LE**, Köbel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. *Lancet Oncol* 2011; **12**: 1071-1080 [PMID: 21616717 DOI: 10.1016/S1470-2045(11)70058-4]

20 **Baba Y**, Huttenhower C, Nosho K, Tanaka N, Shima K, Hazra A, Schernhammer ES, Hunter DJ, Giovannucci EL, Fuchs CS, Ogino S. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. *Mol Cancer* 2010; **9**: 125 [PMID: 20507599 DOI: 10.1186/1476-4598-9-125]

21 **Hamilton SR**, Bosman FT, Boffeta P. (2010) Carcinoma of the colon and rectum. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. Lyon, France: IARC Press; 134–146

22 **Umar A**, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004; **96**: 261-268 [PMID: 14970275 DOI: 10.1093/jnci/djh034]

23 **Terada T**. An immunohistochemical study of primary signet-ring cell carcinoma of the stomach and colorectum: III. Expressions of EMA, CEA, CA19-9, CDX-2, p53, Ki-67 antigen, TTF-1, vimentin, and p63 in normal mucosa and in 42 cases. *Int J ClinExpPathol* 2013; **6**: 630-638 [PMID: 23573309]

24 **Kim JH**, Bae JM, Kim KJ, Rhee YY, Kim Y, Cho NY, Lee HS, Chang MS, Kang GH. Differential Features of Microsatellite-Unstable Colorectal Carcinomas Depending on EPCAM Expression Status. *Korean J Pathol* 2014; **48**: 276-282 [PMID: 25214859 DOI: 10.4132/KoreanJPathol.2014.48.4.276]

25 **Jayanand SB**, Seshadri RA, Tapkire R. Signet ring cell histology and non-circumferential tumors predict pathological complete response following neoadjuvant chemoradiation in rectal cancers. *Int J Colorectal Dis* 2011; **26**: 23-27 [PMID: 21046123 DOI: 10.1007/s00384-010-1082-7]

26 **Lemmens VE**, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. *Int J Cancer* 2011; **128**: 2717-2725 [PMID: 20715167 DOI: 10.1002/ijc.25596]

27 **Klaver YL**, Lemmens VE, Creemers GJ, Rutten HJ, Nienhuijs SW, de Hingh IH. Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. *Ann Oncol* 2011; **22**: 2250-2256 [PMID: 21345939 DOI: 10.1093/annonc/mdq762]

28 **Segelman J**, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. *Br J Surg* 2012; **99**: 699-705 [PMID: 22287157 DOI: 10.1002/bjs.8679]

29 **Verwaal VJ**, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA.Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. *J ClinOncol* 2003; **21**: 3737-3743 [PMID: 14551293 DOI: 10.1200/JCO.2003.04.187]

30 **Sadeghi B**, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. *Cancer* 2000; **88**: 358-363 [PMID: 10640968 DOI: 10.1002/(SICI)1097-0142(20000115)88]

31 **Chu DZ**, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. *Cancer* 1989; **63**: 364-367 [PMID: 2910444 DOI: 10.1002/1097-0142(19890115)63]

32 **Bloemendaal AL**, Verwaal VJ, van Ruth S, Boot H, Zoetmulder FA. Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: a prospective study. *Eur J SurgOncol* 2005; **31**: 1145-1151 [PMID: 16084051 DOI: 10.1016/j.ejso.2005.06.002]

33 **Kuijpers AM**, Mirck B, Aalbers AG, Nienhuijs SW, de Hingh IH, Wiezer MJ, van Ramshorst B, van Ginkel RJ, Havenga K, Bremers AJ, de Wilt JH, TeVelde EA, Verwaal VJ. Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. *Ann SurgOncol* 2013; **20**: 4224-4230 [PMID: 23897008]

34 **van Oudheusden TR**, Braam HJ, Nienhuijs SW, Wiezer MJ, van Ramshorst B, Luyer P, de Hingh IH. Poor outcome after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis with signet ring cell histology. *J SurgOncol* 2015; **111**: 237-242 [PMID: 25195780 DOI: 10.1002/jso.23784]

35 **Chua TC**, Pelz JO, Kerscher A, Morris DL, Esquivel J. Critical analysis of 33 patients with peritoneal carcinomatosis secondary to colorectal and appendiceal signet ring cell carcinoma. *Ann SurgOncol* 2009; **16**: 2765-2770 [PMID: 19641972 DOI: 10.1245/s10434-009-0536-z]

36 **Sammartino P**, Sibio S, Biacchi D, Cardi M, Mingazzini P, Rosati MS, Cornali T, Sollazzo B, Atta JM, Di Giorgio A. Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases. *Int J Colorectal Dis* 2014; **29**: 1081-1089 [PMID: 24980687 DOI: 10.1007/s00384-014-1929-4]

37 **Hao H**, Zhen Y, Wang Z, Chen F, Xie X. A novel therapeutic drug for colon cancer: EpCAMscFv-truncated protamine (tp)-siRNA. *Cell BiolInt* 2013; **37**: 860-864 [PMID: 23576466 DOI: 10.1002/cbin.10112]

38 **Klaver CE**, Musters GD, Bemelman WA, Punt CJ, Verwaal VJ, Dijkgraaf MG, Aalbers AG, van der Bilt JD, Boerma D, Bremers AJ, Burger JW, Buskens CJ, Evers P, van Ginkel RJ, van Grevenstein WM, Hemmer PH, de Hingh IH, Lammers LA, van Leeuwen BL, Meijerink WJ, Nienhuijs SW, Pon J, Radema SA, van Ramshorst B, Snaebjornsson P, Tuynman JB, TeVelde EA, Wiezer MJ, de Wilt JH, Tanis PJ. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. *BMC Cancer* 2015; **15**: 428 [PMID: 26003804 DOI: 10.1186/s12885-015-1430-7]

**P-Reviewer:** Dong SZ **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Table 1 Demographic parameters**

|  |  |
| --- | --- |
| **Parameter** | **Statistics** |
| Total No. | 170 |
| Sex Ratio |  |
| Male | 110 |
| Female | 60 |
| Age (Median), yr | 41  |
| Stage, *n* (%) |  |
| II | 6 (3.5) |
| III | 88 (51.8) |
| IV | 67 (39.4) |
| Not Available | 9 (5.3) |
| Location, *n* (%) |  |
| Right Colon | 49 (28.8) |
| Transverse Colon | 13 (7.6) |
| Descending Colon | 11 (6.5) |
| Sigmoid Colon | 23 (13.5) |
| Rectum | 70 (41.2) |
| Appendix | 1 (0.6) |
| Not Available | 3 (1.8) |

**Table 2 Pattern of metastases in stage IV patients**

|  |  |
| --- | --- |
| **Site of metastases** | ***n* (%)** |
| Liver | 1 (1.5) |
| Lung | 1 (1.5) |
| Isolated Peritoneal  | 58 (86.5) |
| Retroperitoneal Lymphnodes | 2 (3.1) |
| Others | 5 (7.4) |

**Table 3 Pattern of recurrence after curative surgery**

|  |  |
| --- | --- |
| **Pattern of Recurrence** | ***n* (%)** |
| Locoregional | 4 (12.12) |
| Distant | 4 (12.12) |
| Isolated Peritoneal  | 21 (63.63) |
| Peritoneal + Second primary | 2 (6.06) |
| Local + Peritoneal | 2 (3.4) |

Regional Recurrences: Regional lymph node recurrences; Distant Recurrences: Non-regional lymph nodal and visceral recurrences.

**Table 4 Factors affecting overall survival**

|  |  |  |
| --- | --- | --- |
| **Parameter** | **OS (mo)** | **Significance** |
| Location (After curative surgery) |   |   |
| Colon | 32.3 | 0.058 |
| Rectum | 40.1 |  |
| CRM |  |  |
| Positive | 19.9 | 0.018 |
| Negative | 41.5 |  |
| Metastases |  |  |
| Peritoneal | 14.85 | 0.729 |
| Non-peritoneal | 11.14 |  |

CRM: Circumferential resection margin.

**Table 5 Factors affecting relapse free survival in operated patients**

|  |  |  |
| --- | --- | --- |
| **Parameter** | **RFS (mo)** | **Significance** |
| CRM |   |   |
| Positive | 15.003 | 0.06 |
| Negative | 37.202 |  |
| Location |  |  |
| Colon | 24.74 | 0.048 |
| Rectum | 34.02 |  |

RFS: Relapse Free Survival; CRM: Circumferential resection margin.

**Table 6 Impact of location on outcome**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **Colon** | **Rectum** | **Significance** |
| **Recurrence after curative resection** |  |  |  |
| Peritoneal, *n* (%) | 15/40 (37.5) | 8/48 (16.7) | 0.062 |
| Non-peritoneal, *n* (%) | 3/40 (7.5) | 7/48 (14.6) |  |
| Pattern of Metastases at presentation |  |  |  |
| Peritoneal, *n* (%) | 45/49 (91.8) | 15/18 (83.3) | 0.074 |
| Non-peritoneal, *n* (%) | 4/49 (9.2) | 3/18 (16.7) |  |
| RFS (mo) | 24.74 | 34.02 | 0.048 |
| Overall Survival (mo) | 26.011 | 30.32 | 0.062 |
| OS after curative surgery (mo)  | 32.298 | 40.089 | 0.058 |

RFS: Relapse Free Survival; OS: Overall survival.